Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation
Background/Aims Finite nucleos(t)ide analog (NA) therapy has been proposed as an alternative treatment strategy for chronic hepatitis B (CHB), but biomarkers for post-treatment monitoring are limited. We investigated whether measuring hepatitis B core-related antigen (HBcrAg) after NA cessation may stratify the risk of subsequent clinical relapse (CR). Methods This retrospective multicenter analysis enrolled adults with CHB who were prospectively monitored after discontinuing entecavir or tenofovir with negative HBeAg and undetectable HBV DNA at the end of treatment (EOT). Patients with cirrhosis or malignancy were excluded. CR was defined as serum alanine aminotransferase < two times the upper limit of normal with recurrent viremia. We applied time-dependent Cox proportional hazard models to clarify the association between HBcrAg levels and subsequent CR. Results The cohort included 203 patients (median age, 49.8 years; 76.8% male; 60.6% entecavir) who had been treated for a median of 36.9 months (interquartile range [IQR], 36.5–40.1). During a median post-treatment follow-up of 31.7 months (IQR, 16.7–67.1), CR occurred in 104 patients with a 5-year cumulative incidence of 54.8% (95% confidence interval [CI], 47.1–62.4%). Time-varying HBcrAg level was a significant risk factor for subsequent CR (adjusted hazard ratio [aHR], 1.53 per log U/mL; 95% CI, 1.12–2.08) with adjustment for EOT HBsAg, EOT anti-HBe, EOT HBcrAg and time-varying HBsAg. During follow-up, HBcrAg <1,000 U/mL predicted a lower risk of CR (aHR, 0.41; 95% CI, 0.21–0.81). Conclusions Dynamic measurement of HBcrAg after NA cessation is predictive of subsequent CR and may be useful to guide post-treatment monitoring..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Clinical and Molecular Hepatology - 30(2024), 1, Seite 98-108 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ying-Nan Tsai [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Antiviral treatment |
|---|
| doi: |
10.3350/cmh.2023.0194 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ09785171X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ09785171X | ||
| 003 | DE-627 | ||
| 005 | 20240413195731.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3350/cmh.2023.0194 |2 doi | |
| 035 | |a (DE-627)DOAJ09785171X | ||
| 035 | |a (DE-599)DOAJe6cca0a680c349dfb2095f17e98b207d | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC799-869 | |
| 100 | 0 | |a Ying-Nan Tsai |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background/Aims Finite nucleos(t)ide analog (NA) therapy has been proposed as an alternative treatment strategy for chronic hepatitis B (CHB), but biomarkers for post-treatment monitoring are limited. We investigated whether measuring hepatitis B core-related antigen (HBcrAg) after NA cessation may stratify the risk of subsequent clinical relapse (CR). Methods This retrospective multicenter analysis enrolled adults with CHB who were prospectively monitored after discontinuing entecavir or tenofovir with negative HBeAg and undetectable HBV DNA at the end of treatment (EOT). Patients with cirrhosis or malignancy were excluded. CR was defined as serum alanine aminotransferase < two times the upper limit of normal with recurrent viremia. We applied time-dependent Cox proportional hazard models to clarify the association between HBcrAg levels and subsequent CR. Results The cohort included 203 patients (median age, 49.8 years; 76.8% male; 60.6% entecavir) who had been treated for a median of 36.9 months (interquartile range [IQR], 36.5–40.1). During a median post-treatment follow-up of 31.7 months (IQR, 16.7–67.1), CR occurred in 104 patients with a 5-year cumulative incidence of 54.8% (95% confidence interval [CI], 47.1–62.4%). Time-varying HBcrAg level was a significant risk factor for subsequent CR (adjusted hazard ratio [aHR], 1.53 per log U/mL; 95% CI, 1.12–2.08) with adjustment for EOT HBsAg, EOT anti-HBe, EOT HBcrAg and time-varying HBsAg. During follow-up, HBcrAg <1,000 U/mL predicted a lower risk of CR (aHR, 0.41; 95% CI, 0.21–0.81). Conclusions Dynamic measurement of HBcrAg after NA cessation is predictive of subsequent CR and may be useful to guide post-treatment monitoring. | ||
| 650 | 4 | |a chronic hepatitis b | |
| 650 | 4 | |a antiviral treatment | |
| 650 | 4 | |a finite nucleos(t)ide analog therapy | |
| 650 | 4 | |a hepatitis b core-related antigen | |
| 653 | 0 | |a Diseases of the digestive system. Gastroenterology | |
| 700 | 0 | |a Jia-Ling Wu |e verfasserin |4 aut | |
| 700 | 0 | |a Cheng-Hao Tseng |e verfasserin |4 aut | |
| 700 | 0 | |a Tzu-Haw Chen |e verfasserin |4 aut | |
| 700 | 0 | |a Yi-Ling Wu |e verfasserin |4 aut | |
| 700 | 0 | |a Chieh-Chang Chen |e verfasserin |4 aut | |
| 700 | 0 | |a Yu-Jen Fang |e verfasserin |4 aut | |
| 700 | 0 | |a Tzeng-Huey Yang |e verfasserin |4 aut | |
| 700 | 0 | |a Mindie H. Nguyen |e verfasserin |4 aut | |
| 700 | 0 | |a Jaw-Town Lin |e verfasserin |4 aut | |
| 700 | 0 | |a Yao-Chun Hsu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Clinical and Molecular Hepatology |d Korean Association for the Study of the Liver, 2017 |g 30(2024), 1, Seite 98-108 |w (DE-627)DOAJ00002659X |x 2287285X |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2024 |g number:1 |g pages:98-108 |
| 856 | 4 | 0 | |u https://doi.org/10.3350/cmh.2023.0194 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/e6cca0a680c349dfb2095f17e98b207d |z kostenfrei |
| 856 | 4 | 0 | |u http://e-cmh.org/upload/pdf/cmh-2023-0194.pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2287-2728 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2287-285X |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2024 |e 1 |h 98-108 | ||